MolDX: NRAS Genetic Testing

MolDX covers NRAS somatic mutation testing of tumor tissue only for patients with metastatic colorectal cancer per NCCN Guidelines v2.2016 to guide anti-EGFR therapy decisions. All other NRAS testing, including testing for other tumor types and germline testing for Noonan syndrome, is non-covered due to insufficient evidence of clinical utility. The policy requires documentation of tumor tissue and mCRC diagnosis; no frequency limits are specified in the policy.

"NRAS somatic mutation testing of tumor tissue is covered for patients with metastatic colorectal cancer (mCRC) to inform anti-EGFR therapy decisions, per NCCN Guidelines v2."

Sign up to see full coverage criteria, indications, and limitations.